Project

An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD 20+ malignant disease

Automatically Closed · 2009 until 2013

Driessen Christoph, Hitz Felicitas, Hofmann Erika